AstraZeneca: Company Update
Please join us Thursday, March 21 for dinner and a presentation by Christer Gruvris, Investor Relations Director of AstraZeneca.
Dinner: Filet Mignon
Registration also includes one free drink
Free to Members! Only $10 for Non-Members and Registered CFA Program Candidates if pre-paid online!
Event Eligible for one hour CFA Institute CE Credit.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit: www.astrazeneca.com
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least 6 new medicines to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms -- immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates -- and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
Investor Relations Director, AstraZeneca
Christer has worked at AstraZeneca since 2009 in different departments including R&D Finance, Group Treasury, Operations Finance and Group Financial Planning & Analysis (FP&A). Christer’s current role as a Director of Investor Relations includes interacting with buy- and sell-side analysts, preparing press releases including earnings announcements and providing market updates to management. Christer studied at the School of Business, Economics and Law, University of Gothenburg, Sweden, and has Master degrees in Financial Economics, Statistics and Business Administration. Christer is also a Chartered Global Management Accountant (CGMA).